News & Updates
Filter by Specialty:
Post-transplant KRd a new SoC for MM?
In the ongoing phase III ATLAS study evaluating patients with newly diagnosed multiple myeloma (MM), progression-free survival (PFS) was better with maintenance treatment with carfilzomib, lenalidomide, and dexamethasone (KRd) than lenalidomide (R) alone after autologous stem-cell transplantation (ASCT).
Post-transplant KRd a new SoC for MM?
07 Jul 2022
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
Catheter-directed thrombolysis (CDT) is superior to systemic anticoagulation (SA) for the treatment of submassive pulmonary embolism (sPE), leading to better mortality rates without additional safety signals, a recent meta-analysis has found.
Catheter-directed thrombolysis trumps systemic anticoagulation for submassive pulmonary embolism
07 Jul 2022
Diabetes status may influence long-term survival in metastatic breast cancer
Long-term overall survival (OS) in patients with metastatic breast cancer (MBC) may be influenced by diabetes status, according to a retrospective study presented at ENDO 2022.
Diabetes status may influence long-term survival in metastatic breast cancer
06 Jul 2022
Bariatric surgery cuts obesity-associated cancer, cancer death risks
For individuals with obesity, undergoing weight-loss surgery may be a lifesaver, not only helping avert cancer-related deaths but also preventing the incidence of obesity-associated cancer, according to data from the SPLENDID (Surgical Procedures and Long-term Effectiveness in Neoplastic Disease Incidence and Death) study.
Bariatric surgery cuts obesity-associated cancer, cancer death risks
06 Jul 2022
Hypertensive crisis leads to worse outcomes in CKD, ESRD patients
Hypertensive crisis (HTN-C) is a major burden on patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) relative to those without, reveals a study. HTN-C usually results in a higher number of emergency department visits, incidence of hypertensive emergency, hospitalization rate, in-hospital mortality, and cost of care.
Hypertensive crisis leads to worse outcomes in CKD, ESRD patients
06 Jul 2022
Empagliflozin improves outcomes in HFpEF patients regardless of age
Treatment with empagliflozin results in a reduction in heart failure (HF) risk and renal outcomes and in better health-related quality of life (HRQoL) among patients with chronic HF with preserved ejection fraction (HFpEF), a study has shown. In addition, the study drug is well tolerated by older patients.